BR112015021806A2 - inibidores de tirosina cinase de bruton - Google Patents

inibidores de tirosina cinase de bruton

Info

Publication number
BR112015021806A2
BR112015021806A2 BR112015021806A BR112015021806A BR112015021806A2 BR 112015021806 A2 BR112015021806 A2 BR 112015021806A2 BR 112015021806 A BR112015021806 A BR 112015021806A BR 112015021806 A BR112015021806 A BR 112015021806A BR 112015021806 A2 BR112015021806 A2 BR 112015021806A2
Authority
BR
Brazil
Prior art keywords
tyrosine kinase
kinase inhibitors
compounds
bruton tyrosine
diseases associated
Prior art date
Application number
BR112015021806A
Other languages
English (en)
Inventor
Javier Lopez-Tapia Francisco
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015021806A2 publication Critical patent/BR112015021806A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

1/1 resumo inibidores de tirosina cinase de bruton o presente pedido revela compostos de acordo com a fórmula genérica i: em que todas as variáveis são definidas como descrito aqui, que inibem btk. os compostos revelados aqui são úteis para modular a atividade de btk e tratar doenças associadas à atividade de btk excessiva. os compostos são adicionalmente úteis para tratar doenças inflamatórias e auto-imunes associadas à proliferação aberrante de células-b como artrite reumatóide. são também reveladas composições contendo compostos da fórmula i e pelo menos um veículo, diluente ou excipiente.
BR112015021806A 2013-03-05 2014-03-03 inibidores de tirosina cinase de bruton BR112015021806A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772954P 2013-03-05 2013-03-05
PCT/EP2014/054018 WO2014135474A1 (en) 2013-03-05 2014-03-03 Inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
BR112015021806A2 true BR112015021806A2 (pt) 2017-07-18

Family

ID=50190455

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021806A BR112015021806A2 (pt) 2013-03-05 2014-03-03 inibidores de tirosina cinase de bruton

Country Status (11)

Country Link
US (1) US9663494B2 (pt)
EP (1) EP2964642B1 (pt)
JP (1) JP2016510051A (pt)
KR (1) KR101763504B1 (pt)
CN (1) CN105143215B (pt)
BR (1) BR112015021806A2 (pt)
CA (1) CA2903137C (pt)
HK (1) HK1218416A1 (pt)
MX (1) MX2015010983A (pt)
RU (1) RU2015141360A (pt)
WO (1) WO2014135474A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6088063B2 (ja) * 2012-11-16 2017-03-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
US11046670B2 (en) 2015-10-19 2021-06-29 Board Of Regents, The University Of Texas System Piperazinyl norbenzomorphan compounds and methods for using the same
AU2017257153A1 (en) * 2016-04-29 2018-11-22 Board Of Regents, The University Of Texas System Sigma receptor binders
US11100492B2 (en) 2018-02-19 2021-08-24 Peter Garrett General purpose re-loadable card aggregation implementation
DK3774817T3 (da) 2018-04-13 2023-02-13 Cancer Research Tech Ltd Bcl6-hæmmere
WO2022133184A1 (en) * 2020-12-20 2022-06-23 Newave Pharmaceutical Inc. Btk degrader
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053269A1 (en) * 2007-10-23 2009-04-30 F. Hoffmann-La Roche Ag Novel kinase inhibitors
WO2009098144A1 (en) * 2008-02-05 2009-08-13 F. Hoffmann-La Roche Ag Novel pyridinones and pyridazinones
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN102292329B (zh) * 2009-04-24 2014-09-03 霍夫曼-拉罗奇有限公司 布鲁顿酪氨酸激酶的抑制剂
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
JP2015531781A (ja) * 2012-09-13 2015-11-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
MX2015006457A (es) * 2012-11-30 2015-08-14 Hoffmann La Roche Inhibidores de la tirosina cinasa de bruton.

Also Published As

Publication number Publication date
EP2964642B1 (en) 2017-11-15
RU2015141360A (ru) 2017-04-10
KR20150119944A (ko) 2015-10-26
US20150376166A1 (en) 2015-12-31
CA2903137C (en) 2017-07-18
JP2016510051A (ja) 2016-04-04
EP2964642A1 (en) 2016-01-13
MX2015010983A (es) 2015-10-26
CN105143215A (zh) 2015-12-09
CN105143215B (zh) 2017-12-08
WO2014135474A1 (en) 2014-09-12
HK1218416A1 (zh) 2017-02-17
CA2903137A1 (en) 2014-09-12
KR101763504B1 (ko) 2017-07-31
US9663494B2 (en) 2017-05-30

Similar Documents

Publication Publication Date Title
BR112015010693A2 (pt) inibidores de tirosina quinase de bruton
BR112014003582A2 (pt) inibidores da tirosina quinase de bruton
BR112013003114A2 (pt) inibidores de tirosina quinase de bruton
BR112015021806A2 (pt) inibidores de tirosina cinase de bruton
BR112015007513A2 (pt) inibidores de tirosina quinase de bruton
BR112014013582A2 (pt) inibidores de quinase de tirosina de bruton
MX345170B (es) Inhibidores de la tirosina-cinasa de bruton.
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
BR112015021677A2 (pt) inibidores de tirosina quinase de bruton
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
BR112019000247A2 (pt) derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores
BR112019004100A2 (pt) compostos de biarila úteis como imunomoduladores
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
BR112018007381A2 (pt) compostos úteis como imunomoduladores
BR112018068341A2 (pt) 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
BR112018006080A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112018006034A2 (pt) compostos bicíclicos como inibidores de atx
BR112015032595A2 (pt) inibidores de ido
BR112018007395A2 (pt) 2,4-di-hidróxi-nicotinamidas como agonistas de apj
BR112015032664A2 (pt) composições
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2556 DE 31/12/2019.